285 related articles for article (PubMed ID: 17982434)
1. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
Mlynarski W; Tarasov AI; Gach A; Girard CA; Pietrzak I; Zubcevic L; Kusmierek J; Klupa T; Malecki MT; Ashcroft FM
Nat Clin Pract Neurol; 2007 Nov; 3(11):640-5. PubMed ID: 17982434
[TBL] [Abstract][Full Text] [Related]
2. A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
Shimomura K; Hörster F; de Wet H; Flanagan SE; Ellard S; Hattersley AT; Wolf NI; Ashcroft F; Ebinger F
Neurology; 2007 Sep; 69(13):1342-9. PubMed ID: 17652641
[TBL] [Abstract][Full Text] [Related]
3. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
Ješić MM; Ješić MD; Maglajlić S; Sajić S; Necić S
Diabetes Res Clin Pract; 2011 Jan; 91(1):e1-3. PubMed ID: 21056492
[TBL] [Abstract][Full Text] [Related]
4. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation.
Slingerland AS; Hurkx W; Noordam K; Flanagan SE; Jukema JW; Meiners LC; Bruining GJ; Hattersley AT; Hadders-Algra M
Diabet Med; 2008 Mar; 25(3):277-81. PubMed ID: 18307455
[TBL] [Abstract][Full Text] [Related]
5. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
Proks P; Girard C; Baevre H; Njølstad PR; Ashcroft FM
Diabetes; 2006 Jun; 55(6):1731-7. PubMed ID: 16731836
[TBL] [Abstract][Full Text] [Related]
6. Medical and developmental impact of transition from subcutaneous insulin to oral glyburide in a 15-yr-old boy with neonatal diabetes mellitus and intermediate DEND syndrome: extending the age of KCNJ11 mutation testing in neonatal DM.
Mohamadi A; Clark LM; Lipkin PH; Mahone EM; Wodka EL; Plotnick LP
Pediatr Diabetes; 2010 May; 11(3):203-7. PubMed ID: 19686306
[TBL] [Abstract][Full Text] [Related]
7. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
Bremer AA; Ranadive S; Lustig RH
Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
[TBL] [Abstract][Full Text] [Related]
8. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
[TBL] [Abstract][Full Text] [Related]
9. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
Gloyn AL; Pearson ER; Antcliff JF; Proks P; Bruining GJ; Slingerland AS; Howard N; Srinivasan S; Silva JM; Molnes J; Edghill EL; Frayling TM; Temple IK; Mackay D; Shield JP; Sumnik Z; van Rhijn A; Wales JK; Clark P; Gorman S; Aisenberg J; Ellard S; Njølstad PR; Ashcroft FM; Hattersley AT
N Engl J Med; 2004 Apr; 350(18):1838-49. PubMed ID: 15115830
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
Flechtner I; de Lonlay P; Polak M
Diabetes Metab; 2006 Dec; 32(6):569-80. PubMed ID: 17296510
[TBL] [Abstract][Full Text] [Related]
11. Transition from insulin to glyburide in a 4-month-old girl with neonatal diabetes mellitus caused by a mutation in KCNJ11.
Chan YM; Laffel LM
Pediatr Diabetes; 2007 Aug; 8(4):235-8. PubMed ID: 17659066
[TBL] [Abstract][Full Text] [Related]
12. Infantile spasms as an epileptic feature of DEND syndrome associated with an activating mutation in the potassium adenosine triphosphate (ATP) channel, Kir6.2.
Bahi-Buisson N; Eisermann M; Nivot S; Bellanné-Chantelot C; Dulac O; Bach N; Plouin P; Chiron C; de Lonlay P
J Child Neurol; 2007 Sep; 22(9):1147-50. PubMed ID: 17890419
[TBL] [Abstract][Full Text] [Related]
13. Sulfonylurea-responsive diabetes in childhood.
Landau Z; Wainstein J; Hanukoglu A; Tuval M; Lavie J; Glaser B
J Pediatr; 2007 May; 150(5):553-5. PubMed ID: 17452235
[TBL] [Abstract][Full Text] [Related]
14. KCNJ11 activating mutations are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features.
Gloyn AL; Diatloff-Zito C; Edghill EL; Bellanné-Chantelot C; Nivot S; Coutant R; Ellard S; Hattersley AT; Robert JJ
Eur J Hum Genet; 2006 Jul; 14(7):824-30. PubMed ID: 16670688
[TBL] [Abstract][Full Text] [Related]
15. Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.
Al-Mahdi M; Al Mutair A; Al Balwi M; Hussain K
Ann Saudi Med; 2010; 30(2):162-4. PubMed ID: 20220270
[TBL] [Abstract][Full Text] [Related]
16. [Diabetes in infants may be treated with sulfonylurea as a replacement for insulin].
Lauridsen MH; Boesgaard TW; Pedersen OB; Hansen T; Hertz B
Ugeskr Laeger; 2009 Jun; 171(23):1923-4. PubMed ID: 19500515
[TBL] [Abstract][Full Text] [Related]
17. Successful transition to sulfonylurea in neonatal diabetes, developmental delay, and seizures (DEND syndrome) due to R50P KCNJ11 mutation.
Peña-Almazan S
Diabetes Res Clin Pract; 2015 Apr; 108(1):e18-20. PubMed ID: 25678012
[TBL] [Abstract][Full Text] [Related]
18. Sulphonylurea treatment does not improve psychomotor development in children with KCNJ11 mutations causing permanent neonatal diabetes mellitus accompanied by developmental delay and epilepsy (DEND syndrome).
Sumnik Z; Kolouskova S; Wales JK; Komarek V; Cinek O
Diabet Med; 2007 Oct; 24(10):1176-8. PubMed ID: 17888143
[No Abstract] [Full Text] [Related]
19. [Low doses of sulphonyluria as a successful replacement for insulin therapy in a patient with neonatal diabetes due to a mutation of KCNJ11 gene encoding Kir6.2].
Ille J; Putarek NR; Radica A; Hattersley A; Ellard S; Dumić M
Lijec Vjesn; 2010; 132(3-4):90-3. PubMed ID: 20540435
[TBL] [Abstract][Full Text] [Related]
20. Mutations at the same residue (R50) of Kir6.2 (KCNJ11) that cause neonatal diabetes produce different functional effects.
Shimomura K; Girard CA; Proks P; Nazim J; Lippiat JD; Cerutti F; Lorini R; Ellard S; Hattersley AT; Barbetti F; Ashcroft FM
Diabetes; 2006 Jun; 55(6):1705-12. PubMed ID: 16731833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
